UNSPSC 51412001: Molsidomine

This classification denotes a nitric oxide donor and vasodilator agent with the molecular formula C9H14N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D46583G77X, chemically known as sydnone imine, n-(ethoxycarbonyl)-3-(4-morpholinyl)- but generally known as molsidomine, which bears US NIH Compound Identifier 4239. European Medicines Agency schedules Molsidomine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09044MIG.

UNSPSC 51412001 Molsidomine is a Commodity code covering specific pharmaceutical products purchased by state and local health agencies, fire rescue departments, and pharmacy benefit programs. State and local governments use this code to procure individual medications and pharmaceutical supplies for emergency medical services, state health systems, and employee health benefit programs. Recent solicitations show demand for branded and generic pharmaceuticals supplied through authorized wholesaler networks, with vendors required to maintain FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and comprehensive product documentation including Safety Data Sheets and accessibility conformance reporting.

Recent activity spans multiple jurisdictions and procurement models. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications including Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials for Tampa Fire Rescue, with a due date of April 8, 2026, and an estimated contract value of $40,000.00, offering a 5 percent SLBE bid discount. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs serving state pharmacy benefit initiatives. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) due March 26, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC across Minnesota, Oregon, and other participating jurisdictions, with price competitiveness weighted at 75 percent of evaluation and vendor awards effective July 1, 2026.